Targeted
Medical Pharma, Inc. (OTCQB: TRGM), today announced several major
changes that streamline operations and signify a commitment to revenue
growth, cost containment and profitability. The Company has appointed
Kim Giffoni, a co-founder and former Vice President of Foreign Sales at
Targeted Medical Pharma, as the Chief Executive Officer. Dr. David
Silver, former Chief Operating Officer and President at the Company, has
been appointed Chief Medical Officer, and Marcus Charuvastra, the
Director of Marketing, takes over as Vice President of Operations and
Marketing.
In addition, The Board of Directors has appointed veteran healthcare
specialist Kerry Weems, as the new Chairman of the Board. Mr. Weems will
be replacing Dr. William Shell, a co-founder and former Chief Executive
Officer of the Company, who will remain a non-executive Director. A
nationally respected expert in health policy and government finance, Mr.
Weems has served with distinction in the field of healthcare, including
nearly 28 years in the Federal government, as Acting Administrator of
the Centers for Medicare and Medicaid Services (CMS). Mr. Weems is
currently Chief Executive Officer of TwinMed, a national medical supply
distributor in Los Angeles.
“The new management structure will make Targeted Medical a leaner more
efficient company adding a lot more value for our customers and
shareholders,” said recently appointed CEO, Kim Giffoni. “The company
can now focus on improving and expanding customer relationships as well
as creating new business opportunities domestically and abroad.”
Twitter: @tmedpharma
Facebook: https://www.facebook.com/TargetedMedicalPharma
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company also develops a line of dietary
supplements designed to support health and wellness. The company
manufactures 10 proprietary medical foods, and the dietary supplement
for sinus and immune support, Clearwayz™.
The products are sold directly to physicians, patients and pharmacies in
the United States and abroad.
Forward Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma’s business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaims any obligation
or undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the company's expectations
with regard thereto or any change in events, conditions or circumstances
upon which any statement is based.
Copyright Business Wire 2015